Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in Treatment-Resistant Depression
NCT04979910Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Aug 2021
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixekizumab in treatment-resistant depression (TRD), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Number of Participants Who Dropped-out at 6 weeks and Number of Anticipated and Unanticipated Adverse Events at 6 weeks. Started Aug 2021; status: completed.
02
Drugs
ixekizumab
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT04979910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04979910.